ABT Stock Recent News

With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.

ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the management's ability to reiterate its ambitious FY2025 guidance, despite the supposed hundreds of millions in tariff impact. Combined with the richer Free Cash Flow generation, healthier balance sheet, and high single-digits dividend per share growth, we believe that ABT remains well positioned to outperform ahead.

Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.

Live Updates Live Coverage Has Ended Gaines and Losers Today 12:59 pm Winners: APA Corp (APA) up 5.27% Abbott Labs (ABT) up 4.37% Devon Energy (DVN) up 4.17% Marathon Petroleum (MPC) up 3.82% Losers: NVIDIA (NVDA) down 7.53% JB Hunt (JBHT) down 7.49% MD (AMD) down 7.30% Interpublic Group (IPG) down 5.71% China to Fight Until the End 11:42 am According to The White House press release, China now faces up to 245% tariffs on on imports, up from 145% and despite the number increase, China will “ignore” the numbers gain and plans to fight until the end of the tariff war. As of 11:45 am: Nasdaq Composite: -1.48% S&P 500: -0.74% Dow Jones Industrial Average: -.02% Shares of the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) are down 1% in morning trading Wednesday after Nvidia (NASDAQ:NVDA) announced it would take a massive $5.5 billion writedown in the first quarter. The artificial intelligence chipmaker said in a late-afternoon SEC filing yesterday the U.S. government was imposin

Live Updates Live Coverage Has Ended S&P Sinks 3% in Tech-Fueled Sell-Off 3:21 pm by Gerelyn Terzo Technology stocks are in freefall mode, sending the S&P 500 to its lows of the session for a decline of 3%. Federal Reserve Chairman Jerome Powell addressed the tariffs, saying that they complicate the central bank’s efforts to tame inflation and grow the economy. Policymakers are seeking greater clarity before tweaking monetary policy. Bank of America CEO Brian Moynihan is factoring in zero interest rate cuts in 2025. Magnificent Seven stocks are falling anywhere between 4% and 9.8%, pressuring the S&P 500 and Nasdaq Composite lower. Here’s a look at the damage as of late afternoon trading: Dow Jones Industrial Average: Down 860 (-2%) Nasdaq Composite: Down 709.16 (-4.2%) S&P 500: Down 163.62 (-3.0%) Tech Falls, Energy Rises 1:04 pm by Gerelyn Terzo The markets are mired in losses as tech stocks are sent reeling from the tariff fallout. All three of the major

Abbott Laboratories NYSE: ABT is not immune to the impact of tariffs on its medical device business. However, the company's diversified business is tariff-resistant, and moves are being made to strengthen it further.

I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth.